Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The final invasive disease-free survival analysis displayed efficacy results at 90.7% by 36 months in ribociclib combined with NSAI while 87.6% was in the solo NSAI arm. Common adverse events (AEs) ...
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
Medpage Today on MSN5d
FDA Expands Approval of Ribociclib to Early Breast CancerThe drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...
Opens in a new tab or window The FDA on Tuesday approved ribociclib ... overall survival data remain immature. "The FDA approval of Kisqali for this early breast cancer population, including ...
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
SurvivorNet on MSN5d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of KisqaliThe Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback